News and Press Releases
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 -- Tiziana Life Sciences, Ltd (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...
Category: Clinical Trials
Posted: August 14, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Paris, August 14, 2025: The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation...
Category: Clinical Trials
Posted: August 14, 2025
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
Iksuda Therapeutics receives FDA IND clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025
Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes
France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and...
Category:
Posted: June 25, 2025
Novo Nordisk A/S: Ozempic receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Pending a decision from the European Commission, Ozempic (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 23, 2025
Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers
Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study,...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025
Enhancing Clinical Trials for Faster, More Predictable Outcomes with WCG Study Accelerator
May 28, 2025 – CARY, NC – WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG Study Accelerator, an...
Category: Clinical Trials
Posted: May 29, 2025
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...
Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
• HDP-101 demonstrated complete response in one female patient from cohort 5• R&D Webinar to be hosted on 17 June 2025. 15 May 2025 -- Ladenburg, Germany -- Heidelberg Pharma...
Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 15, 2025
Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO
Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025
Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers
Integrated solution with self-service capabilities simplifies trial experience for all 13 May 2025 -- California, US -- Medable Inc., a leading provider of clinical development and eCOA technology, today announced...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2025
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 10, 2025
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 9, 2025
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025
Campus Biotech Innovation Park Avenue Sécheron 15
1202 Genève
Switzerland
